Seres Therapeutics Inc (NASDAQ:MCRB) – Analysts at Cantor Fitzgerald issued their FY2017 earnings per share estimates for Seres Therapeutics in a report issued on Tuesday, Zacks Investment Research reports. Cantor Fitzgerald analyst W. Tanner forecasts that the biotechnology company will post earnings of ($2.75) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock.
MCRB has been the topic of several other research reports. Zacks Investment Research raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 17th. Canaccord Genuity reissued a “buy” rating and issued a $20.00 price objective on shares of Seres Therapeutics in a research note on Tuesday, January 31st. FBR & Co dropped their price objective on Seres Therapeutics from $23.00 to $18.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 1st. Finally, Cowen and Company reissued a “buy” rating on shares of Seres Therapeutics in a research note on Wednesday, February 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. Seres Therapeutics presently has an average rating of “Buy” and an average target price of $23.20.
WARNING: This piece was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.com-unik.info/2017/04/21/seres-therapeutics-inc-forecasted-to-earn-fy2017-earnings-of-2-75-per-share-mcrb-updated-updated.html.
Shares of Seres Therapeutics (NASDAQ:MCRB) traded down 1.87% during midday trading on Thursday, reaching $9.46. The company’s stock had a trading volume of 152,632 shares. Seres Therapeutics has a 1-year low of $8.05 and a 1-year high of $35.98. The company’s 50-day moving average price is $10.48 and its 200 day moving average price is $10.53. The firm’s market capitalization is $381.88 million.
Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings data on Thursday, March 16th. The biotechnology company reported ($0.63) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.70) by $0.07. The firm earned $3 million during the quarter, compared to analysts’ expectations of $3 million. The company’s quarterly revenue was up NaN% compared to the same quarter last year.
Institutional investors have recently modified their holdings of the company. Artal Group S.A. boosted its position in shares of Seres Therapeutics by 40.0% in the fourth quarter. Artal Group S.A. now owns 700,000 shares of the biotechnology company’s stock worth $6,930,000 after buying an additional 200,000 shares during the last quarter. Ellington Management Group LLC bought a new position in shares of Seres Therapeutics during the fourth quarter worth about $107,000. Renaissance Technologies LLC boosted its position in shares of Seres Therapeutics by 35.0% in the fourth quarter. Renaissance Technologies LLC now owns 400,300 shares of the biotechnology company’s stock worth $3,963,000 after buying an additional 103,800 shares during the last quarter. ARK Investment Management LLC bought a new position in shares of Seres Therapeutics during the fourth quarter worth about $4,871,000. Finally, Trexquant Investment LP boosted its position in shares of Seres Therapeutics by 147.5% in the fourth quarter. Trexquant Investment LP now owns 25,924 shares of the biotechnology company’s stock worth $257,000 after buying an additional 15,450 shares during the last quarter. Institutional investors and hedge funds own 77.62% of the company’s stock.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Seres Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Seres Therapeutics Inc and related companies.